Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 86.24% | -348.00% | -752.06% | 34.66% | -42.52% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -28.57% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.94% | 570.10% | 186.90% | -- | -- |
| Change in Net Operating Assets | -330.06% | 227.12% | 101.59% | -4,557.58% | 88.66% |
| Cash from Operations | -421.02% | 35.60% | 93.31% | -5,531.05% | -13.29% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | -34.78% | -4.55% |
| Cash from Investing | -- | 100.00% | 98.31% | -34.78% | -4.55% |
| Total Debt Issued | -- | -- | -100.00% | 508.70% | 1.86% |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -- | -- | -100.00% | 1,447.38% | 1.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 505.89% | 36.97% | -147.87% | 6,090.19% | -330.11% |